JP2002509889A - 膜型マトリックスメタロプロテイナーゼを阻害する方法 - Google Patents

膜型マトリックスメタロプロテイナーゼを阻害する方法

Info

Publication number
JP2002509889A
JP2002509889A JP2000540834A JP2000540834A JP2002509889A JP 2002509889 A JP2002509889 A JP 2002509889A JP 2000540834 A JP2000540834 A JP 2000540834A JP 2000540834 A JP2000540834 A JP 2000540834A JP 2002509889 A JP2002509889 A JP 2002509889A
Authority
JP
Japan
Prior art keywords
cmt
tetracycline
mmp
dimethylamino
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2000540834A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002509889A5 (cg-RX-API-DMAC7.html
Inventor
ローン エム ゴルーブ
シー ミン リー
ティモ ソルサ
オーリ テローネン
テューラ サロ
Original Assignee
ザ リサーチ ファウンデーション オブ ステイト ユニヴァーシティ オブ ニューヨーク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ リサーチ ファウンデーション オブ ステイト ユニヴァーシティ オブ ニューヨーク filed Critical ザ リサーチ ファウンデーション オブ ステイト ユニヴァーシティ オブ ニューヨーク
Publication of JP2002509889A publication Critical patent/JP2002509889A/ja
Publication of JP2002509889A5 publication Critical patent/JP2002509889A5/ja
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2000540834A 1998-03-31 1999-03-30 膜型マトリックスメタロプロテイナーゼを阻害する方法 Abandoned JP2002509889A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/052,222 1998-03-31
US09/052,222 US6277061B1 (en) 1998-03-31 1998-03-31 Method of inhibiting membrane-type matrix metalloproteinase
PCT/US1999/006972 WO1999049871A1 (en) 1998-03-31 1999-03-30 Method of inhibiting membrane-type matrix metalloproteinase

Publications (2)

Publication Number Publication Date
JP2002509889A true JP2002509889A (ja) 2002-04-02
JP2002509889A5 JP2002509889A5 (cg-RX-API-DMAC7.html) 2006-06-01

Family

ID=21976191

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000540834A Abandoned JP2002509889A (ja) 1998-03-31 1999-03-30 膜型マトリックスメタロプロテイナーゼを阻害する方法

Country Status (8)

Country Link
US (2) US6277061B1 (cg-RX-API-DMAC7.html)
EP (1) EP1079837A4 (cg-RX-API-DMAC7.html)
JP (1) JP2002509889A (cg-RX-API-DMAC7.html)
KR (1) KR20010042322A (cg-RX-API-DMAC7.html)
AU (1) AU748870B2 (cg-RX-API-DMAC7.html)
CA (1) CA2320260A1 (cg-RX-API-DMAC7.html)
NZ (1) NZ506153A (cg-RX-API-DMAC7.html)
WO (1) WO1999049871A1 (cg-RX-API-DMAC7.html)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6506740B1 (en) * 1998-11-18 2003-01-14 Robert A. Ashley 4-dedimethylaminotetracycline derivatives
EP1174129A1 (en) * 2000-07-17 2002-01-23 Zenner, Hans Peter, Prof. Dr. med. Use of a matrix-metalloprotease inhibitor for the treatment of cancer
EP1408987B1 (en) 2001-07-13 2013-04-10 Paratek Pharmaceuticals, Inc. Tetracycline compounds having target therapeutic activities
WO2003030819A2 (en) * 2001-10-05 2003-04-17 Tetragenex Pharmaceuticals, Inc. Tetracycline derivatives and methods of use thereof
CN100391464C (zh) * 2001-12-03 2008-06-04 诺瓦西股份有限公司 含活性维生素d化合物的药物组合物
WO2003053447A1 (en) * 2001-12-20 2003-07-03 Hanauske-Abel Hartmut M Treatment for averting or delaying premature delivery
EP2311797A1 (en) 2002-01-08 2011-04-20 Paratek Pharmaceuticals, Inc. 4-dedimethylamino tetracycline compounds
JP2005526754A (ja) 2002-03-08 2005-09-08 パラテック ファーマシューティカルズ インコーポレイテッド アミノメチル置換されたテトラサイクリン化合物
EP1503981A4 (en) 2002-03-21 2007-08-15 Paratek Pharm Innc SUBSTITUTED TETRACYCLINE COMPOUNDS
WO2003082011A1 (en) * 2002-03-29 2003-10-09 The Research Foundation Of State University Of New York Use of non-antibacterial tetracycline analogs and formulations thereof for the treatment of bacterial exotoxins
WO2004006850A2 (en) 2002-07-12 2004-01-22 Paratek Pharmaceuticals, Inc 3, 10, AND 12a SUBSTITUTED TETRACYCLINE COMPOUNDS
US20040170621A1 (en) * 2002-08-30 2004-09-02 Roodman G. David Method of resisting osteoclast formation
US20040138162A1 (en) * 2002-08-30 2004-07-15 Roodman G. David Method of resisting osteoclast formation
JP4686189B2 (ja) 2002-10-24 2011-05-18 パラテック ファーマシューティカルズ インコーポレイテッド Rnaを調節するための置換テトラサイクリン化合物の使用方法
WO2004060346A2 (en) 2002-12-30 2004-07-22 Angiotech International Ag Drug delivery from rapid gelling polymer composition
WO2005009943A2 (en) 2003-07-09 2005-02-03 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds
JP4738333B2 (ja) 2003-07-09 2011-08-03 パラテック ファーマシューティカルズ インコーポレイテッド 9−アミノメチルテトラサイクリン化合物のプロドラッグ
EP2332904A3 (en) * 2004-01-15 2012-04-11 Paratek Pharmaceuticals, Inc. Derivatives of tetracycline compounds
JP2008518025A (ja) 2004-10-25 2008-05-29 パラテック ファーマシューティカルズ インコーポレイテッド 4−アミノテトラサイクリンおよびその使用の方法
WO2006047756A2 (en) 2004-10-25 2006-05-04 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds
CA2616224A1 (en) * 2005-07-21 2007-02-01 Paratek Pharmaceuticals, Inc. 10-substituted tetracyclines and methods of use thereof
US20070142337A1 (en) * 2005-12-15 2007-06-21 The Regents Of The University Of California Treatment of inflammation and organ dysfunction
PL2120963T3 (pl) 2006-12-21 2019-05-31 Paratek Pharm Innc Podstawione związki tetracyklinowe do leczenia zaburzeń zapalnych skóry
IL270446B2 (en) * 2006-12-21 2023-10-01 Paratek Pharm Innc A tetracycline compound, a pharmaceutical preparation containing the tetracycline compound, and the tetracycline compound or the pharmaceutical preparation for the treatment of the tetracycline-responsive condition
EP2144870A2 (en) * 2007-04-27 2010-01-20 Paratek Pharmaceuticals, Inc. Methods for synthesizing and purifying aminoalkyl tetracycline compounds
WO2009009042A1 (en) * 2007-07-06 2009-01-15 Paratek Pharmaceuticals, Inc. Methods for synthesizing substituted tetracycline compounds
TWI585071B (zh) 2008-05-19 2017-06-01 派洛泰克藥物股份有限公司 四環素化合物之甲苯磺酸鹽及同素異形體
HUE026562T2 (hu) 2008-08-08 2016-06-28 Tetraphase Pharmaceuticals Inc C7-fluor-helyettesített tetraciklin vegyületek
CN102459153A (zh) 2009-05-08 2012-05-16 四相制药公司 四环素类化合物
EP2470500B1 (en) 2009-08-28 2017-10-04 Tetraphase Pharmaceuticals, Inc. Tetracycline compounds
WO2011123536A1 (en) 2010-03-31 2011-10-06 Tetraphase Pharmaceuticals, Inc. Polycyclic tetracycline compounds
LT2707003T (lt) 2011-05-12 2019-10-10 Paratek Pharmaceuticals, Inc. Kristalinės (4s,4as,5ar,12as)-4-dimetilamino-3,10,12,12a-tetrahidroksi-7-[(metoksi(metil)amino)-metil]-1,11-diokso-1,4,4a,5,5a,6,11,12a-oktahidro-naftacen-2-karboksirūgšties amido druskos ir jų panaudojimo būdai
TR201902057T4 (tr) 2012-08-31 2019-03-21 Tetraphase Pharmaceuticals Inc Tetrasiklin bileşikleri.
MA46567A (fr) 2016-10-19 2019-08-28 Tetraphase Pharmaceuticals Inc Formes cristallines de l'éravacycline
WO2020097450A1 (en) 2018-11-09 2020-05-14 Tetraphase Pharmaceuticals, Inc. Polymorphic forms of a compound and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704383A (en) * 1983-12-29 1987-11-03 The Research Foundation Of State University Of New York Non-antibacterial tetracycline compositions possessing anti-collagenolytic properties and methods of preparing and using same
US4925833A (en) * 1983-12-29 1990-05-15 The Research Foundation Of State University Of New York Use of tetracycline to enhance bone protein synthesis and/or treatment of osteoporosis
AU1411992A (en) 1991-01-15 1992-08-27 Robert A Bok A composition containing a tetracycline and use for inhibiting angiogenesis
JPH06256280A (ja) * 1992-11-17 1994-09-13 Univ New York State 糖尿病における過度のコラーゲン架橋結合を阻害する非抗菌性化学修飾テトラサイクリンを含むテトラサイクリン
US5668122A (en) * 1993-07-28 1997-09-16 Fife; Rose S. Method to treat cancer with tetracyclines
GB9615976D0 (en) 1996-07-30 1996-09-11 Center For Clinical & Basic Re The use of proteinase inhibitors for the prevention or reduction of bone resorption
US5789395A (en) * 1996-08-30 1998-08-04 The Research Foundation Of State University Of New York Method of using tetracycline compounds for inhibition of endogenous nitric oxide production
US5837696A (en) 1997-01-15 1998-11-17 The Research Foundation Of State University Of New York Method of inhibiting cancer growth

Also Published As

Publication number Publication date
NZ506153A (en) 2003-10-31
AU3457699A (en) 1999-10-18
US6277061B1 (en) 2001-08-21
US20020045603A1 (en) 2002-04-18
WO1999049871A8 (en) 1999-12-02
CA2320260A1 (en) 1999-10-07
AU748870B2 (en) 2002-06-13
WO1999049871A1 (en) 1999-10-07
EP1079837A4 (en) 2003-07-02
EP1079837A1 (en) 2001-03-07
KR20010042322A (ko) 2001-05-25

Similar Documents

Publication Publication Date Title
AU748870B2 (en) Method of inhibiting membrane-type matrix metalloproteinase
JP4428727B2 (ja) 癌の成長を抑制する方法
Vartak et al. Matrix metalloproteases: underutilized targets for drug delivery
JP4339411B2 (ja) 疎水性テトラサイクリンによるセリンプロテイナーゼ阻害活性
Johnson et al. Matrix metalloproteinases
ES2237945T3 (es) Combinacion de bisfosfonato y tetraciclina.
US7638127B2 (en) Peptide conjugated anti-cancer prodrugs
JP2676080B2 (ja) 非抗バクテリア性テトラサイクリン組成物
DE69322659T2 (de) Pharmazeutische zubereitung enthaltend eine beta-lactam antibiotikum abbauende verbindung, und deren verwendung
US20090269405A1 (en) Enzyme mediated delivery system
Lee et al. CMT-3, a non-antimicrobial tetracycline (TC), inhibits MT1-MMP activity: relevance to cancer
EP1459738A1 (en) Pharmaceutical composition having thrombolytic, anti-inflammatory and cytoprotective properties
JP2002506881A (ja) 新規マトリックスメタロプロテイナーゼ阻害剤および下方調節剤
US6429204B1 (en) Method of inhibiting cancer growth
US20070027064A1 (en) Pharmaceutical compositions for inhibiting metal ion dependent enzymatic activity and methods for the use thereof
JP4630661B2 (ja) 線維症および瘢痕形成の治療におけるコンバターゼインヒビターの使用
EP0369035A1 (en) Agent for treating pancreatitis or the like
KR100274172B1 (ko) 타입 iv 콜라게네이즈 활성을 억제하는 timp-2 유래 합성펩타이드
Rathna et al. Recent Insights of Matrix Metalloproteinase Inhibitors in Therapeutic Applications
US20020151481A1 (en) MMP-2 propeptide for use as antiangiogenic or antitumor agent
Naidu et al. Lefty peptides, derived by MMP2 cleavage, act as a new class of gelatinase A inhibitor
Riedlinger et al. Metastatic melanoma and matrix metalloproteinases
Acid Correlation of Antiangiogenic and Antitumor Efficacy of
MXPA99006554A (en) Method of inhibiting cancer growth
WILLIAMS-HERMAN et al. metalloproteinases) and intracellular degradation involving lysosomal proteolysis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060329

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060329

A762 Written abandonment of application

Free format text: JAPANESE INTERMEDIATE CODE: A762

Effective date: 20071228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20071228